Atsena Therapeutics Appoints Linda B. Couto, Ph.D., as Chief Scientific Officer
UF startup Atsena Therapeutics, a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness, announced the appointment of Linda B. Couto, Ph.D., as Chief Scientific Officer (CSO).
Atsena Therapeutics Acquires Exclusive Rights to Gene Therapy for GUCY2D-Associated Leber Congenital Amaurosis
UF startup Atsena Therapeutics, a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent... Read More
Unraveling Genetic Mutations
Listen to Shannon Boye, Ph.D., an associate professor of pediatrics at the University of Florida, talk about her journey in academia and... Read More
